logo
Share SHARE
FONT-SIZE Plus   Neg

Dixons Retail 12-week Sales Rise, Sees Pre-tax Profit In Line With Market View

Specialist electrical retail and services firm Dixons Retail Plc. (DXNS.L) Thursday reported a 2 percent growth in total sales for the 12-week period ended January 5, with a like-for-like sales growth of 3 percent. Sales improved 4 percent at local currency.

Looking ahead to the full year, the company expects underlying profit before tax to be in line with market view of 75 million pounds to 85 million pounds.

In UK & Ireland, total sales increased 7 percent both in Sterling and local currency. On a like-for-like basis, sales rose 8 percent from last year. Northern Europe continued its strong performance, with like-for-like sales improving 11 percent for the 12-week period.

In Southern Europe, comprising Italy, Greece, Turkey, like-for-like sales dropped 8 percent from the previous year.

Sebastian James, chief executive of the company stated, "Our key multi-channel businesses delivered an encouragingly strong result during the Christmas period, particularly in the UK & Ireland and in Northern Europe."

Meanwhile, its single-channel business PIXmania had a poor period impacted by ongoing restructuring of the business, in addition to significant negative trends in its main markets. However, Dixons noted that progress continues on the restructuring plan to improve financial position of the business.

Group gross margins were down 0.5 percent, driven mainly by product mix.

In London, Dixons Retail shares are currently trading at 27.36 pence, up 0.90 percent, on a volume of 21.21 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

0 Articles
Editors Pick
Foodservice distributor Sysco Corp. (SYY) reported a third-quarter profit that grew 22.7 percent from last year, while quarterly sales increased 2.2 percent. Both earnings per share and revenue for the quarter beat analysts' expectations. Halliburton Co. (HAL) and Baker Hughes Inc. (BHI) announced Sunday that they terminated the merger agreement they entered into in November 2014, effective April 30, 2016. In connection with the termination of the merger agreement, Halliburton will pay Baker Hughes the termination fee of $3.5 billion... The bench to bedside journey of drugs is fraught with challenges. It is estimated that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and out of those 5, only 1 may pass through all the regulatory hurdles needed to reach pharmacy shelves.
comments powered by Disqus
Follow RTT